Semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are both GLP-1s that function very similarly
Dorchester Center, MA 02124 Contents While GLP-1 receptor agonists like Ozempic and Wegovy have dominated recent headlines, the human body possesses remarkable capabilities to naturally enhance its own GLP-1 production
That distinction matters because it changes the entire conversation
As of July 2026, retatrutide (LY3437943) remains an investigational drug in Phase 3 clinical trials (Eli Lilly's TRIUMPH program)
Glucagon receptor activation is examined for its relationship with hepatic glucose output, lipolysis, and energy-expenditure pathways central to weight loss research
Medical weight loss intervention has been skyrocketing in recent years with many drugs on the market or in clinical trials, including incretin memetics or incretin receptor agonists such as Ozempic (semaglutide, SEMA) targeting glucagon-like peptide-1 (GLP-1) receptor (GLP1R) or dual agonist Mounjaro (tirzepatide) targeting GLP1R and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR)
